Antoniu Sabina Antonela
a Department of Medicine II-Nursing/Palliative Care , University of Medicine and Pharmacy Grigore T Popa Iasi , Iasi , Romania.
Expert Opin Investig Drugs. 2018 Feb;27(2):139-146. doi: 10.1080/13543784.2018.1427728. Epub 2018 Jan 25.
Bronchiectasis not related to cystic fibrosis (non-CF bronchiectasis) are associated with a high unmet therapeutic need due to the lack of specifically authorized medications, especially via the inhalation route. In non-CF bronchiectasis chronic infection with Pseudomonas aeruginosa is common and favored by the persistent local inflammation and viscid sputum production. Therefore inhaled antibiotics, mucolytics or anti-inflammatory agents could represent appropriate therapeutic interventions in this setting.
This review herein discusses the inhaled therapies currently under investigation for non-CF bronchiectasis and their potential therapeutic positioning in exacerbation versus stable state.
Inhaled antipseudomonal antibiotics are of promising efficacy, but further efforts should also be made to detect bactericidal approaches against Burkholderia cepacia complex, and to interfere chronic inflammation topically.
由于缺乏专门批准的药物,尤其是吸入途径的药物,与囊性纤维化无关的支气管扩张症(非囊性纤维化支气管扩张症)存在高度未满足的治疗需求。在非囊性纤维化支气管扩张症中,铜绿假单胞菌的慢性感染很常见,且持续的局部炎症和粘稠痰液的产生会促进这种感染。因此,吸入抗生素、粘液溶解剂或抗炎剂可能是这种情况下合适的治疗干预措施。
本综述讨论了目前正在研究的用于非囊性纤维化支气管扩张症的吸入疗法及其在急性加重期与稳定期的潜在治疗定位。
吸入抗假单胞菌抗生素具有良好的疗效,但还应进一步努力寻找针对洋葱伯克霍尔德菌复合体的杀菌方法,并局部干预慢性炎症。